...
首页> 外文期刊>BMC Infectious Diseases >SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients
【24h】

SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients

机译:肾脏替代疗法中的抽样抗生素(SMARRT):危重病患者的观察药代动力学研究

获取原文
           

摘要

Background Optimal antibiotic dosing is key to maximising patient survival, and minimising the emergence of bacterial resistance. Evidence-based antibiotic dosing guidelines for critically ill patients receiving RRT are currently not available, as RRT techniques and settings vary greatly between ICUs and even individual patients. We aim to develop a robust, evidence-based antibiotic dosing guideline for critically ill patients receiving various forms of RRT. We further aim to observe whether therapeutic antibiotic concentrations are associated with reduced 28-day mortality. Methods/Design We designed a multi-national, observational pharmacokinetic study in critically ill patients requiring RRT. The study antibiotics will be vancomycin, linezolid, piperacillin/tazobactam and meropenem. Pharmacokinetic sampling of each patient’s blood, RRT effluent and urine will take place during two separate dosing intervals. In addition, a comprehensive data set, which includes the patients’ demographic and clinical parameters, as well as modality, technique and settings of RRT, will be collected. Pharmacokinetic data will be analysed using a population pharmacokinetic approach to identify covariates associated with changes in pharmacokinetic parameters in critically ill patients with AKI who are undergoing RRT for the five commonly prescribed antibiotics. Discussion Using the comprehensive data set collected, the pharmacokinetic profile of the five antibiotics will be constructed, including identification of RRT and other factors indicative of the need for altered antibiotic dosing requirements. This will enable us to develop a dosing guideline for each individual antibiotic that is likely to be relevant to any critically ill patient with acute kidney injury receiving any of the included forms of RRT. Trial registration Australian New Zealand Clinical Trial Registry ( ACTRN12613000241?730 ) registered 28 February 2013
机译:背景技术最佳抗生素给药是最大化患者存活的关键,并最大限度地减少细菌抗性的出现。目前不可用的循证抗生素给药指南,接受RRT的危重病症,因为RRT技术和环境在ICU甚至个别患者之间有很大差异。我们的目标是制定一种稳定,基于循证的抗生素给药指南,用于接受各种形式的RRT患者。我们进一步观察治疗性抗生素浓度是否与28天死亡率降低有关。方法/设计我们设计了一个需要RRT的批评患者的多国,观测药代动力学研究。该研究抗生素将是万古霉素,LINEzolid,Piperacillin / Tazobactam和Meropenem。在两种单独的给药间隔内将发生每个患者血液,RRT流出物和尿液的药代动力学取样。此外,将收集一个综合数据集,包括患者人口统计和临床参数,以及RRT的模态,技术和设置。使用人口药代动力学方法将分析药代动力学数据,以鉴定与患有患者患者的药代动力学参数的变化相关的协调因子,该患者正在持续5例常规规定的抗生素接受RRT的AKI。讨论采用综合数据集收集的,将构建五种抗生素的药代动力学曲线,包括鉴定RRT和其他因素,指示需要改变抗生素给药要求的需求。这将使我们能够为每种抗生素制定给药指南,该指南可能与任何具有急性肾损伤的任何批评性患者相关的患者,接受任何包含的RRT形式。审判登记澳大利亚新西兰临床试验登记处(ACTRN12613000241?730)2013年2月28日注册

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号